KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Gains from Investment Securities (2020 - 2025)

AbCellera Biologics' Gains from Investment Securities history spans 6 years, with the latest figure at -$3.6 million for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities rose 78.14% year-over-year to -$3.6 million, compared with a TTM value of $3.3 million through Dec 2025, down 83.03%, and an annual FY2025 reading of $3.3 million, down 83.03% over the prior year.
  • Gains from Investment Securities for Q4 2025 was -$3.6 million at AbCellera Biologics, down from $2.5 million in the prior quarter.
  • The five-year high for Gains from Investment Securities was $37.0 million in Q2 2022, with the low at -$23.1 million in Q4 2022.
  • Average Gains from Investment Securities over 5 years is $3.3 million, with a median of $2.6 million recorded in 2021.
  • Year-over-year, Gains from Investment Securities surged 43453.57% in 2021 and then plummeted 818.21% in 2022.
  • Tracing ABCL's Gains from Investment Securities over 5 years: stood at $3.2 million in 2021, then plummeted by 818.21% to -$23.1 million in 2022, then surged by 55.81% to -$10.2 million in 2023, then crashed by 59.2% to -$16.3 million in 2024, then surged by 78.14% to -$3.6 million in 2025.
  • Per Business Quant, the three most recent readings for ABCL's Gains from Investment Securities are -$3.6 million (Q4 2025), $2.5 million (Q3 2025), and $2.6 million (Q2 2025).